Abstract: A method for sample alignment is applied to a first participant system, where a first trusted execution environment is deployed at the first participant system. The method includes, in the first trusted execution environment, obtaining at least one first sample identifier of the first participant system; through the first trusted execution environment, obtaining at least one second sample identifier of the second participant system from the second trusted execution environment, where the second trusted execution environment is deployed at the second participant system; in the first trusted execution environment, determining the first initial intersection of the at least one first sample identifier and the at least one second sample identifier and performing the shuffle processing on all first target sample identifiers in the first initial intersection to obtain the first target intersection; and based on the first target intersection, determining the first sample alignment result.

Abstract: Provided are a method, apparatus and device for detecting a field curvature of a VR optical module, wherein a diaphragm is fixed on a lens of a camera, a first electronic control is used to drive the VR optical module to self-rotate around an optical axis of a VR lens, and a second electronic control is used to drive the camera to swing in a plane where the optical axis of the VR lens is located with a center of the diaphragm as a fixed point.

Abstract: The present invention provides a molecular marker C42257 for rapidly identifying genetic sex of Marsupenaeus japonicus and applications thereof. The nucleotide sequence of the molecular marker C42257 is shown in SEQ ID NO:1. The nucleotide sequences of the primer pair of molecular marker C42257 used for detection are C42257F: GGGGGACAA ACAGAGACA (SEQ ID NO: 2) and C42257R: ATCGGGGTGGATTTAGAA (SEQ ID NO: 3), respectively. The molecular marker C42257 is not affected by the tissue specificity of M. japonicus and the environment, and the steps are simple and the results are obvious. The genomic DNA of M. japonicus and the primer pair are subjected to PCR reaction and electrophoresis detection. If a target band appears at 183 bp, it is a female M. japonicus. The molecular marker can also promote the establishment of the seedling breeding technology of all-female or high-female-ratio M. japonicus. Therefore, it has a broad application prospect.

Abstract: Provided are a method, apparatus and device for detecting a field curvature of a VR optical module, wherein a diaphragm is fixed on a lens of a camera, a first electronic control is used to drive the VR optical module to self-rotate around an optical axis of a VR lens, and a second electronic control is used to drive the camera to swing in a plane where the optical axis of the VR lens is located with a center of the diaphragm as a fixed point.

Abstract: A vehicle includes a contactor electrically between a charge port and a traction battery, and a controller configured to maintain the contactor in a closed position until a charge current estimate, derived from vehicle load data without sensing current through the contactor or receiving data from a charge station regarding the current, is less than a predetermined threshold. The maintenance of the contactor position is responsive to a charge disconnect request.

Abstract: A method for screening a compound capable of regulating gene expression by binding to a transcription product particularly for obtaining a drug candidate compound. The method includes selecting a stem-loop structure as a desired motif in an RNA, inputting a parameter of a specific stem-loop structure, and executing a plurality of RNA higher-order structural analysis programs to search/extract a sequence that can assume the structure in a molecule thereof from an mRNA sequence, selecting a specific target sequence in a specific transcription product as an indicator of the position at which the stem-loop structure is present in the molecule in an mRNA having significance for development of a potential drug target in an object disease or the like from the extracted mRNA, designing/preparing a labeling probe on the basis of the sequence, performing screening using the labeling probe as an assessment system, and acquiring a low-molecular-weight compound that selectively stabilizes the stem-loop structure.

Abstract: A nucleic acid medicine for managing a disease or disorder related to unwanted gene expression. A technique for efficiently regulating gene expression in a cell using a relatively short oligonucleotide, by establishing a method for designing a nucleic acid medicine, that includes performing structural analysis based on sequence information of a target RNA sequence as an object for gene expression regulation, calculating the probability of existence of each structure from the results of the structural analysis and the energy of each structure, and calculating the existence probability in unified fashion of an endogenous stem-loop substructure, thereby specifying a more favorable endogenous stem-loop substructure. This technique can theoretically be applied to regulation expression of any gene, and is useful for treatment or prevention of various diseases and disorders.

Abstract: A vehicle includes a contactor electrically between a charge port and a traction battery, and a controller configured to maintain the contactor in a closed position until a charge current estimate, derived from vehicle load data without sensing current through the contactor or receiving data from a charge station regarding the current, is less than a predetermined threshold. The maintenance of the contactor position is responsive to a charge disconnect request.

Abstract: Provided are an aptamer having an inhibitory activity against NGF; a complex containing an aptamer having a binding activity or inhibitory activity against NGF and a functional substance (e.g., affinity substances, labeling substances, enzymes, drug delivery vehicles, drugs and the like); a medicament, a diagnostic agent, a labeling agent and the like containing an aptamer having a binding activity or inhibitory activity against NGF, or a complex containing the aptamer and the functional substance; and the like.

Abstract: Provided by the present invention are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or labeling agent containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.

Abstract: Provided by the present invention are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or labeling agent containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.

Abstract: The present invention provides an aptamer binding to NGF and capable of forming a potential secondary structure represented by the formula (I): wherein N is one nucleotide selected from the group consisting of A, G, C, U and T, N11-N13, N21-N23, N32-N38 and N42-N48 are the same or different and each is a bond or 1 or 2 nucleotides selected from the group consisting of A, G, C, U and T, N14, N24, N31, N41, N39 and N49 are the same or different and each is one nucleotide selected from the group consisting of A, G, C, U and T, N14 and N24, N31 and N41, and N39 and N49 each form a Watson-Crick base pair, N11-N12-N13-N14 and N21-N22-N23-N24 are nucleotide sequences capable of forming a stem structure in combination, and N31-N32-N33-N34-N35-N36-N37-N38-N39 and N41-N42-N43-N44-N45-N46-N47-N48-N49 are nucleotide sequences capable of forming a stem structure in combination.

Abstract: A method and apparatus provide live call text-to-speech. The method can include entering an ongoing voice call at a first communication device with a second communication device. The method can include receiving text input at the first communication device during the ongoing voice call. The method can include converting the text input to speech during the ongoing voice call to generate a text-to-speech audible signal. The method can include sending the text-to-speech audible signal from the first communication device to the second communication device during the ongoing voice call.

Abstract: A method and apparatus provide live call text-to-speech. The method can include entering an ongoing voice call at a first communication device with a second communication device. The method can include receiving text input at the first communication device during the ongoing voice call. The method can include converting the text input to speech during the ongoing voice call to generate a text-to-speech audible signal. The method can include sending the text-to-speech audible signal from the first communication device to the second communication device during the ongoing voice call.

Abstract: Provided is a higher quality aptamer having a binding activity to NGF. An aptamer binding to NGF, which satisfies the following (1) and (2): (1) containing the sequence represented by UGAAARAAACC (SEQ ID NO: 64) or CGAAMRAAACU (SEQ ID NO: 65), and (2) having a base length of not more than 73.

Abstract: Sending apparatus, receiving apparatus, sending method, receiving method and sending and receiving system for supporting application based MMS. The body of an incremental MMS includes a dynamic data section of MMS, a static data indicator associated with the MMS, and a link tag between indicated static data and the dynamic data. The amount of the message quantity transmitted may be reduced because the changed section of the incremental MMS is sent directly via short message channel in dynamic data mode. In turn, the incremental MMS may be sent via short message channel instead of MMS channel due to the reduction of transmitted message, which further reduces the communication cost.

Abstract: Provided are an aptamer bound to chymase to inhibit activity of chymase; an aptamer containing a nucleotide sequence represented by X1GAUAGAN1N2UAAX2 wherein X1 and X2 are the same or different and each is A or G, and N1 and N2 are the same or different and each is A, G, C, U or T; a complex containing the aptamer and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery medium, drug and the like); a pharmaceutical or a reagent containing the aptamer or complex; a detection and a purification methods of chymase using the aptamer or complex and the like.

Abstract: Sending apparatus, receiving apparatus, sending method, receiving method and sending and receiving system for supporting application based MMS. The body of an incremental MMS includes a dynamic data section of MMS, a static data indicator associated with the MMS, and a link tag between indicated static data and the dynamic data. The amount of the message quantity transmitted may be reduced because the changed section of the incremental MMS is sent directly via short message channel in dynamic data mode. In turn, the incremental MMS may be sent via short message channel instead of MMS channel due to the reduction of transmitted message, which further reduces the communication cost.

Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Abstract: The present invention provides an aptamer binding to NGF and capable of forming a potential secondary structure represented by the formula (I): wherein N is one nucleotide selected from the group consisting of A, G, C, U and T, N11-N13, N21-N23, N32-N38 and N42-N48 are the same or different and each is a bond or 1 or 2 nucleotides selected from the group consisting of A, G, C, U and T, N14, N24, N31, N41, N39 and N49 are the same or different and each is one nucleotide selected from the group consisting of A, G, C, U and T, N14 and N24, N31 and N41, and N39 and N49 each form a Watson-Crick base pair, N11-N12-N13-N14 and N21-N22-N23-N24 are nucleotide sequences capable of forming a stem structure in combination, and N31-N32-N33-N34-N35-N36-N37-N38-N39 and N41-N42-N43-N44-N45-N46-N47-N48-N49 are nucleotide sequences capable of forming a stem structure in combination.